Pinetree Therapeutics is an award-winning, pre-clinical stage biotechnology company based in Cambridge, Massachusetts. Dedicated to addressing unmet medical needs, such as drug resistance and tumor recurrence in targeted therapy, Pinetree Therapeutics is advancing the field with its novel AbReptorTM platform. While the primary focus is on oncology, Pinetree Therapeutics is expanding pipelines to other areas as well.
The AbReptorTM platform enables the development of multi-specific antibodies designed to outperform conventional inhibitors and ADCs (Antibody Drug Conjugate) by degradation. Unlike traditional inhibitors, which are limited in their mechanism of action (blocking the signaling pathway), our antibodies demonstrate superior efficacy in targeting and degrading disease proteins. The platform's focus is on targeted degradation of membrane-bound and extracellular proteins, offering a distinct advantage over conventional inhibitors and intracellular degraders like PROTACs or GLUEs. Additionally, the unique mechanism of our platform has yielded promising preclinical results in ADC (/DAC/ARC) application, demonstrating its potential to significantly advance the field.
-
所属行业
-
生物技术
-
规模
-
11-50 人
-
总部
-
Cambridge，Massachusetts
-
类型
-
私人持股
-
创立
-
2019
-
领域
-
Oncology、NSCLC、solid cancer、Pancreatic cancer、Bispecific antibody和Breast cancer
